How ChatGPT and Gemini Describe CROs and CDMOs: A First Look

When a sponsor, biotech founder or procurement lead asks ChatGPT "Which CROs are best for a Phase II oncology trial?", a short list of companies comes back. Most commercial teams have no idea whether they are on it, or what AI says about them when they are.

We asked ChatGPT, Gemini, Perplexity and Google's AI Overviews how they describe and compare 15 CROs and CDMOs. This session is a first look at what we found.

What we will cover
• Who gets named, who gets missed, and how often AI gets capabilities wrong
• Why some providers show up for therapeutic areas and modalities while others only appear when searched by name
• What seems to drive visibility: content, third-party mentions, entity signals
• Three things your marketing and BD team can check this week
Agenda (45 minutes)
• 5 min: Why AI answers now shape vendor shortlists
• 15 min: Snapshot findings
• 10 min: What drives visibility
• 15 min: Open Q&A

Who should attend
CCOs, CBOs, VPs and directors of marketing and business development, and marketing teams at CROs, CDMOs, biotech, tools and life science service companies.

Details
Online. The joining link is sent after you RSVP.
Tuesday, November 17, 2026, 2:00 to 2:45 PM ET (11:00 AM PT).
Can't make it live? RSVP anyway and we will send the recording.

Life sciences professionals only. No sales pitches.